In the past week, MCRB stock has gone up by 40.61%, with a monthly gain of 53.62% and a quarterly surge of 5.45%. The volatility ratio for the week is 13.32%, and the volatility levels for the last 30 days are 11.19% for Seres Therapeutics Inc The simple moving average for the last 20 days is 54.38% for MCRB stock, with a simple moving average of -34.65% for the last 200 days.
Is It Worth Investing in Seres Therapeutics Inc (NASDAQ: MCRB) Right Now?
The 36-month beta value for MCRB is at 1.96. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MCRB is 119.44M, and currently, shorts hold a 14.76% of that float. The average trading volume for MCRB on May 06, 2024 was 4.38M shares.
MCRB) stock’s latest price update
Seres Therapeutics Inc (NASDAQ: MCRB)’s stock price has increased by 4.50 compared to its previous closing price of 1.11. However, the company has seen a 40.61% increase in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-05 that Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2023 Earnings Call Transcript March 5, 2024 8:30 AM ET Company Participants Rob Windsor – IR Eric Shaff – CEO Terri Young – CCO & CSO Lisa von Moltke – CMO David Arkowitz – CFO Dave Ege – CTO Matthew Henn – Chief Scientific Officer Conference Call Participants Jeff Jones – Oppenheimer John Newman – Canaccord Tess Romero – JPMorgan Peyton Bohnsack – TD Cowen Chris Shibutani – Goldman Sachs Keay Nakae – Chardan Operator Ladies and gentlemen, good morning. My name is Abby, and will be your conference operator today.
Analysts’ Opinion of MCRB
Many brokerage firms have already submitted their reports for MCRB stocks, with Oppenheimer repeating the rating for MCRB by listing it as a “Outperform.” The predicted price for MCRB in the upcoming period, according to Oppenheimer is $12 based on the research report published on June 26, 2023 of the previous year 2023.
JP Morgan, on the other hand, stated in their research note that they expect to see MCRB reach a price target of $7. The rating they have provided for MCRB stocks is “Neutral” according to the report published on April 21st, 2023.
Goldman gave a rating of “Sell” to MCRB, setting the target price at $7 in the report published on July 23rd of the previous year.
MCRB Trading at 37.77% from the 50-Day Moving Average
After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.47% of loss for the given period.
Volatility was left at 11.19%, however, over the last 30 days, the volatility rate increased by 13.32%, as shares surge +52.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.45% upper at present.
During the last 5 trading sessions, MCRB rose by +40.61%, which changed the moving average for the period of 200-days by -75.42% in comparison to the 20-day moving average, which settled at $0.7712. In addition, Seres Therapeutics Inc saw -17.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MCRB starting from Shaff Eric D., who sale 11,549 shares at the price of $1.08 back on Feb 16 ’24. After this action, Shaff Eric D. now owns 135,321 shares of Seres Therapeutics Inc, valued at $12,473 using the latest closing price.
Ege David S., the of Seres Therapeutics Inc, sale 5,010 shares at $1.08 during a trade that took place back on Feb 16 ’24, which means that Ege David S. is holding 73,856 shares at $5,411 based on the most recent closing price.
Stock Fundamentals for MCRB
Current profitability levels for the company are sitting at:
- -0.89 for the present operating margin
- 0.92 for the gross margin
The net margin for Seres Therapeutics Inc stands at -0.91. The total capital return value is set at -0.43. Equity return is now at value -538.57, with -32.15 for asset returns.
Based on Seres Therapeutics Inc (MCRB), the company’s capital structure generated 1.71 points at debt to capital in total, while cash flow to debt ratio is standing at -1.08. The debt to equity ratio resting at -2.41. The interest coverage ratio of the stock is -8.54.
Currently, EBITDA for the company is -92.17 million with net debt to EBITDA at -0.84. When we switch over and look at the enterprise to sales, we see a ratio of 2.07. The receivables turnover for the company is 14.56for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.78.
Conclusion
In conclusion, Seres Therapeutics Inc (MCRB) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
